Table 3.

Post hoc analyses of the SUPERIOR trial

	Placebo (n = 47)	Meropenem (n = 44)	% difference (95% CIs)	Odds ratio (95% CIs)	p value
Delta SOFA 72 h without LOCF, median (Q1 to Q3)	0 (− 1 to 1)a	− 1 (− 2 to 0)b	NA	NA	0.005
Delta SOFA 96 h without LOCF, median (Q1 to Q3)	0 (− 1 to 0)c	− 1 (− 2 to 0)d	NA	NA	0.033
Modified empiric treatment after culture results, n (%)	24 (51.1)	18 (40.9)	10.2 (− 10 to 29.2)	0.66 (0.29 to 1.52)	0.402
Escalation, n (%)	8 (17)	8 (18.2)	1.1 (− 14.6 to 17.2)	1.08 (0.37 to 3.2)	1.00
De-escalation, n (%)	16 (34)	10 (22.7)	11.3 (− 7.3 to 28.7)	0.57 (0.23 to 1.44)	0.255
No change, n (%)	23 (48.9)	26 (59.1)	10.2 (− 10 to 29.2)	1.51 (0.66 to 3.5)	0.402
Source control performed, n (%)	4 (8.5)	6 (13.6)	5.1 (− 8.4 to 19.2)	1.70 (0.45 to 6.5)	0.514
Renal abscess drainage, n (%)	2 (4.3)	1 (2.3)	2 (− 8 to 12.2)	0.52 (0.05 to 6)	1.00
Pleural effusion/ empyema drainage, n (%)	2 (4.3)	1 (2.3)	2 (− 8 to 12.2)	0.52 (0.05 to 6)	1.00
Pigtail removal, n (%)	0	1 (2.3)	2.3 (− 5.5 to 11.8)	0.5 (0.4 to 0.6)	0.484
Percutaneous transhepatic drainage, n (%)	0	1 (2.3)	2.3 (− 5.5 to 11.8)	0.5 (0.4 to 0.6)	0.484
Gangrene toe amputation, n (%)	0	1 (2.3)	2.3 (− 5.5 to 11.8)	0.5 (0.4 to 0.6)	0.484
Surgery for diverticulitis, n (%)	0	1 (2.3)	2.3 (− 5.5 to 11.8)	0.5 (0.4 to 0.6)	0.484
Need for ICU hospitalization, n (%)	1 (2.1)	1 (2.3)	0.15 (− 9 to 10)	1.05 (0.1 to 17.3)	1.00

n Number of patients, LOCF last observation carried forward, ICU intensive care unit, Q quartile

^aThe total number of patients in the placebo group without LOCF was 44

^bThe total number of patients in the meropenem group without LOCF was 41

^cThe total number of patients in the placebo group without LOCF was 42

^dThe total number of patients in the meropenem group without LOCF was 41